Akin Ozturk

Akin Ozturk

Auto-generated profile, based on publicly available information

Akin Ozturk

Department of Medical Oncology Outpatient Clinic, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Heliyon
Verified
Journal Article
Open access
SKSİNAN KOCA
SİNAN KOCA
EKEsra Koca
Esra Koca
İÖİlker Nihat Ökten
İlker Nihat Ökten
FOFatma Fc. Orengül
Fatma Fc. Orengül
AOAkın Oztürk
Akın Oztürk
MGMahmut Gümüş
Mahmut Gümüş
Although cancer patients have a high risk of exposing COVID-19 and developing severe complications, they have to receive active treatment. We aimed to determine the psychological conditions of cancer patients and shed light on the establishment of early psychological intervention and intervention policies by making specific recommendations. We consecutively evaluated 385 cancer patients under treatment. Post-traumatic stress disorder (PTSD) symptoms, depression, anxiety, stress, and associated sociodemographic/clinical characteristics were investigated. In addition, we applied depression-anxiety-stress-scale-21 (DASS-21) for the mental states of patients and Impact of Event-Scale-Revised (IES-R) for the psychological effects of Covid-19. The mean age was 58 (18–88). 47.2% were psychologically distressful per DASS-21, and 39.3% were traumatic per IES-R scores. 71.9% stated the risk of getting COVID-19 was high since they had cancer, and 82% stated serious complications would develop if they had COVID-19 infection. Patients diagnosed for more than one year were more stressed, anxious, and depressive (p–value = 0.001,0.003,0.049, respectively). Singles were more stressed, depressed, and traumatized than couples (p-value = 0.001, 0.011, 0.001). In multivariate analysis, a significant correlation with being under psychiatric treatment before the pandemic was found for depression (OR: 3.743, 95 %CI: 1.790–7.827) anxiety (OR: 3.776–95 %CI: 1.945–7.332) and stress levels (OR: 4.129, 95 %CI: 1.728–9.866). Having relatives who died or received treatment for COVID-19(OR: 0.515,0.296–0.895) and being unmarried (OR: 2.445–95% CI: 1.260–4.747) predicts PTSD development. When the psychological effects of the COVID-19 pandemic are manifesting strongly, cancer patients' anxiety and exposure levels are high. It is of great importance that clinicians understand needs, recognize psychological distress, and direct them to relevant departments for supportive care.

17 February 2024 in Postgraduate Medicine
Verified
Journal Article
Closed access
FTFaruk Tas
Faruk Tas
AOAkın Ozturk
Akın Ozturk
KEKayhan Erturk
Kayhan Erturk
Body mass index (BMI) and serum albumin (ALB) level are long-established markers that reflect the nutritional status and eventually the prognosis of cancer patients. The objective of the study was to determine the clinical significance of these factors and specify their roles in outcomes compared with performance status (PS) and weight loss (WL), which are considered the most significant patient-related prognostic factors in small cell lung cancer (SCLC) treated with platinum-etoposide-based chemotherapy. A total of 378 patients with SCLC were enrolled in the study and analyzed retrospectively. BMI values were similar by clinical stage, whereas the percentages of the patients with WL, low serum ALB, and particularly poor (≥2) PS were significantly higher in patients with extended disease SCLC (ED-SCLC) compared to those with limited disease SCLC (LD-SCLC). In LD-SCLC, patients with poor PS lived for a significantly shorter time than patients with good PS (HR: 7.791, p = 0.0001); however, BMI (HR: 1.035, p = 0.8), WL (HR: 0.857, p = 0.5), and ALB (HR: 0.743, p = 0.3) had no significant effect on the outcome. In ED-SCLC, PS (HR: 4.257, p = 0.0001), WL (HR: 1.677, p = 0.001), and ALB (HR: 0.680, p = 0.007) had an impact on survival, but BMI did not (HR: 0.791, p = 0.08). In LD-SCLC, the univariate analysis showed that only poor PS was correlated with increased mortality (HR: 7.791, p = 0.0001); yet it lost significance in multivariate analysis. In ED-SCLC, poor PS (HR: 4.257, p = 0.0001), WL (HR: 1.667, p = 0.001), and a low ALB level (HR: 0.680, p = 0.007) were shown to be factors for poor prognosis in the univariate analysis; yet only PS remained significant in multivariate analysis (HR: 2.286, p = 0.001). Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.

14 May 2022 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
ATAtakan Topcu
Atakan Topcu
AOAkin Ozturk
Akin Ozturk
IYIsmail Yurtsever
Ismail Yurtsever
MBMehmet Besiroglu
Mehmet Besiroglu
AYAyse Irem Yasin
Ayse Irem Yasin
MSMesut Seker
Mesut Seker
Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.

20 June 2019 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
MKMurat Kavas
Murat Kavas
AOAkin Ozturk
Akin Ozturk
ODOnur Derdiyok
Onur Derdiyok
CACansel Atinkaya
Cansel Atinkaya
SUSenol Urek
Senol Urek
IYIrfan Yalcinkaya
Irfan Yalcinkaya
Turkthoracj, Turkish Thoracic Journal

22 January 2024 in Journal of Chemotherapy
Verified
Journal Article
Closed access
FTFaruk Tas
Faruk Tas
AOAkin Ozturk
Akin Ozturk
KEKayhan Erturk
Kayhan Erturk
Systemic chemotherapy is the backbone of therapeutic management in small cell lung cancer (SCLC) and delay of treatment may lead to adverse patient outcomes. This study was conducted to determine the time elapsed between pathological diagnosis and initiation of chemotherapy in SCLC patients and to evaluate its clinical significance. A total of 323 pathologically confirmed SCLC patients were enrolled in the study and analyzed retrospectively. The median value of the patients' time to treatment was used as the cut-off value in distinguishing between early and late chemotherapy. The median (range) of the time interval between the pathological diagnosis and the initiation of chemotherapy was 18 days (1-257). Compared with other clinical variables, only the performance status of patients was significantly associated with the time from diagnosis to initiation of chemotherapy; patients with poor prognostic factors received chemotherapy earlier than other patients (32.9 vs 18.9%, p = 0.004, and 14.5 vs 19 days, p = 0.006). Although patients who received early treatment were found to live less, there was no statistically significant difference in overall survival in patients according to the timing of chemotherapy administration (p = 0.08). In conclusion, there are controversial results about the timing of chemotherapy administration to SCLC patients. More standardized definitions and guides for calculation of the time interval between diagnosis and treatment are needed to better understand the delays in the treatment of patients with clinically rapidly disseminating SCLC.

5 March 2023 in Online Türk Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
MKMurat Kavas
Murat Kavas
CBCansel Ati̇nkaya Baytemi̇r
Cansel Ati̇nkaya Baytemi̇r
MAMurat Alisik
Murat Alisik
AÖAkın ÖZTÜRK
Akın ÖZTÜRK
SBSümeyye Alparslan Beki̇r
Sümeyye Alparslan Beki̇r
ÖEÖzcan EREL
Özcan EREL
Objective: Lung cancer has a poor prognosis. Thiol groups with high antioxidant capacity are converted to disulfide bonds through biochemical reactions that neutralize different oxidant compounds. The thiol-disulfide (SH-SS) homeostasis has significant effects on cell mechanisms, transcription, and apoptosis. Here we present the prognostic role of dynamic SH-SS homeostasis in patients operated for NSCLC. Materials and Methods: Patients operating for early-stage NSCLC were prospectively analyzed. SH-SS homeostasis tests were measured using the automated spectrophotometric method. Results: This study enrolled 138 subjects, including 77 patients and 61 healthy controls. Native thiol and total thiol levels were significantly lower in the patient group. The disulfide-to-native thiol ratio, which is an indicator of oxidative stress in SH-SS homeostasis, also reached a level of statistical significance in the patient group (p<0.001). According to the cut-off values (305 and 326.3), the median overall survival rate was significantly shorter in patients with low native thiol and total thiol levels (p<0.001). Conclusions: This study demonstrated decreased native thiol and total thiol levels as well as decreased disulfide levels and SS/SH ratio in early-stage NSCLC. Impaired SH-SS homeostasis may contribute to lung cancer pathogenesis and poor prognosis because of enhanced oxidative stress.